The antibody drug market has huge space. In 2017, the global antibody drug market exceeded 100 billion US dollars for the first time. Monoclonal antibody drugs have become the fastest-growing segment in the global biopharmaceutical industry. Compared with the market size of hundreds of billions of dollars in the international market, the domestic monoclonal antibody market is currently far behind developed countries in terms of research and development level, product types and sales scale, and has huge market potential.
Hotgen H2007 therapeutic monoclonal antibody has successfully obtained multiple high-activity monoclonal antibodies, basically clarifying the mechanism of action, preliminary research confirmed that H2007 therapeutic monoclonal antibody has the most popular tumor immunotherapy drugs PD-1 / PDL-1 It has a similar effect, and combined with PD-1 / PDL-1 is more effective in anti-tumor therapy.